JoAnn Lindenfeld

Oct 29, 2024 | healio.com | Erik Swain |Richard Smith |B. Hadley Wilson |JoAnn Lindenfeld

B. Hadley Wilson, MD, FACC The key message here is that it does appear beneficial to consider doing TAVR on patients with moderate aortic stenosis and HFrEF. Two reasons that came out were that the TAVR group did better on the KCCQ score and reported symptomatic improvements, and that in the surveillance group, by 2 to 3 years, the majority of patients either underwent TAVR or expired.